These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37495297)

  • 1. Immunosuppressive Therapy in Solid Organ Transplantation: Primer for Radiologists and Potential Complications.
    Tammisetti VS; Prasad SR; Dasyam N; Menias CO; Katabathina V
    Radiol Clin North Am; 2023 Sep; 61(5):913-932. PubMed ID: 37495297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs.
    Parlakpinar H; Gunata M
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):651-665. PubMed ID: 34415233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of Immunosuppressive Therapy in Solid Organ Transplantation.
    Katabathina V; Menias CO; Pickhardt P; Lubner M; Prasad SR
    Radiol Clin North Am; 2016 Mar; 54(2):303-19. PubMed ID: 26896226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Hypertension Because of Immunosuppressive Therapy After Solid Organ Transplantation-Pharmacological Approach.
    Gilewski W; Banach J; Rogowicz D; Wołowiec Ł; Sielski S; Grześk G
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):735-744. PubMed ID: 34001720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
    Gutierrez-Dalmau A; Campistol JM
    Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients.
    Asberg A; Jardine AG; Bignamini AA; Rollag H; Pescovitz MD; Gahlemann CC; Humar A; Hartmann A;
    Am J Transplant; 2010 Aug; 10(8):1881-8. PubMed ID: 20486914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Immunosuppression Management: Opportunities and Uncertainties.
    Wojciechowski D; Wiseman A
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1264-1271. PubMed ID: 33853841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression in solid organ-transplant recipients and impact on nutrition support.
    Wilson NK; Kataria AD
    Nutr Clin Pract; 2024 Feb; 39(1):109-116. PubMed ID: 38030572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern immunosuppression after solid organ transplantation].
    Beimler J; Morath C; Zeier M
    Internist (Berl); 2014 Feb; 55(2):212-22. PubMed ID: 24518922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Immunosuppression in Solid Organ Transplantation.
    Konda P; Golamari R; Eisen HJ
    Handb Exp Pharmacol; 2022; 272():267-285. PubMed ID: 35318509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of opportunistic infections in solid-organ transplantation.
    Chiu LM; Domagala BM; Park JM
    Prog Transplant; 2004 Jun; 14(2):114-29. PubMed ID: 15264456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
    Plosker GL; Foster RH
    Drugs; 2000 Feb; 59(2):323-89. PubMed ID: 10730553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression in the pediatric transplant recipient.
    Blondet NM; Healey PJ; Hsu E
    Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.
    Prokai A; Fekete A; Pasti K; Rusai K; Banki NF; Reusz G; Szabo AJ
    Pediatr Diabetes; 2012 Feb; 13(1):81-91. PubMed ID: 21595806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.
    Aguado JM; Torre-Cisneros J; Fortún J; Benito N; Meije Y; Doblas A; Muñoz P
    Clin Infect Dis; 2009 May; 48(9):1276-84. PubMed ID: 19320593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current State of Immunosuppression: Past, Present, and Future.
    Karam S; Wali RK
    Crit Rev Eukaryot Gene Expr; 2015; 25(2):113-34. PubMed ID: 26080606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive drugs and associated complications in abdominal organ transplantation.
    Olson JC
    Curr Opin Crit Care; 2022 Apr; 28(2):208-215. PubMed ID: 35142726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.